Diplomat to Dispense Cholesterol-Lowering Drug, REPATHA™
FLINT, Mich. – September 9, 2015 – The nation’s largest independent specialty pharmacy will offer REPATHA™ (evolocumab) to treat patients with high cholesterol.
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it will offer REPATHA™ (evolocumab), recently approved by the U.S. Food and Drug Administration, to treat patients with hereditary forms of high cholesterol and those at risk of cardiovascular disease.
REPATHA™ is indicated as an adjunct to diet and maximally tolerated statin therapy for adult patients with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease. REPATHA™ is also indicated as an adjunct to diet and other low-density lipoprotein-lowering therapies for the treatment of patients with homozygous familial hypercholesterolemia.
REPATHA™ is an antibody that targets PCSK9 (proprotein convertase subtilisin kexin type 9), a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol (LDL-C) from the blood. Mutations in the PCSK9 gene are often linked to high cholesterol, and REPATHA™ works to dramatically reduce these levels.
“Statins are the most widely prescribed class of medications for those with high cholesterol, and for those who are statin-intolerant, finding treatment can be difficult,” said Gary Kadlec, Diplomat’s president. “With REPATHA™, we are motivated by the thought of offering those patients a new innovative means of treatment.”
High cholesterol, particularly elevated LDL-C, is the most common form of dyslipidemia, which is an abnormality of cholesterol and/or fats in the blood. Nearly one in three Americans have elevated LDL-C, which is recognized as a major risk factor for cardiovascular disease.
REPATHA™ is distributed by Amgen Inc. Please see full prescribing information for REPATHA™ at http://pi.amgen.com/united_states/repatha/repatha_pi_hcp_english.pdf.
To learn more about Diplomat, visit www.diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | firstname.lastname@example.org
Gary Rice, RPh, MS, MBA, CSP, Vice President,
810.768.9863 | email@example.com
@DiplomatRxDiplomat to Acquire LDI Integrated Pharmacy Services https://t.co/l9hgIF91i53 days ago
@BusLeadersforMIRT @BusLeadersforMI: VIDEO: Phil Hagerman of @DiplomatRx @SkypointFlint gets the crowd at the 2017 #MICEOSummit fired up about Flint! https…3 days ago
@DiplomatRxIn an instant, Donna graduated from Stage 3 survivor to Stage 4 patient. In dancing, she found the therapy needed t… https://t.co/I5ouNXJI9W4 days ago
@BusLeadersforMIRT @BusLeadersforMI: .@DiplomatRx & @SkypointFlint CEO Phil Hagerman addresses the sold-out 6th annual MI CEO Summit! #MICEOSummit https://…2 weeks ago
@BusLeadersforMIRT @BusLeadersforMI: Great update on the exciting projects underway in Flint from @DiplomatRx @SkypointFlint CEO Phil Hagerman at the sold-…2 weeks ago